Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin A  COVID-19 treatment studies for Vitamin A  C19 studies: Vitamin A  Vitamin A   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Hospitalization 26% Improvement Relative Risk Recovery, dyspnea 32% Recovery, fever 80% Recovery, body ache 87% Recovery, headache 49% Recovery, weakness and.. 63% Recovery, chest pain 20% Recovery, cough 40% c19early.com/va Rohani et al. IRCT46974 Vitamin A RCT EARLY TREATMENT Favors vitamin A Favors control
Rohani, 180 patient vitamin A early treatment RCT: 26% lower hospitalization [p=0.63] and 32% improved recovery [p=0.53] https://c19p.org/rohani
copied to clipboard
Evaluation and comparison of the effect of vitamin A supplementation with standard therapies in the treatment of patients with COVID-19
Rohani et al., Eastern Mediterranean Health Journal, doi:10.26719/emhj.22.064, IRCT46974
18 Aug 2022    Source   PDF   Share   Tweet
RCT 91 vitamin A and 91 control patients in Iran, showing improved recovery with treatment. All patients received HCQ. 25,000IU/day oral vitamin A for 10 days.
risk of hospitalization, 25.6% lower, RR 0.74, p = 0.63, treatment 8 of 89 (9.0%), control 11 of 91 (12.1%), NNT 32.
risk of no recovery, 31.8% lower, RR 0.68, p = 0.53, treatment 4 of 89 (4.5%), control 6 of 91 (6.6%), NNT 48, dyspnea.
risk of no recovery, 79.6% lower, RR 0.20, p = 0.03, treatment 2 of 89 (2.2%), control 10 of 91 (11.0%), NNT 11, fever.
risk of no recovery, 87.2% lower, RR 0.13, p = 0.01, treatment 1 of 89 (1.1%), control 8 of 91 (8.8%), NNT 13, body ache.
risk of no recovery, 48.9% lower, RR 0.51, p = 0.32, treatment 3 of 89 (3.4%), control 6 of 91 (6.6%), NNT 31, headache.
risk of no recovery, 62.8% lower, RR 0.37, p = 0.05, treatment 4 of 89 (4.5%), control 11 of 91 (12.1%), NNT 13, weakness and fatigue.
risk of no recovery, 20.5% lower, RR 0.80, p = 0.63, treatment 7 of 89 (7.9%), control 9 of 91 (9.9%), NNT 49, chest pain.
risk of no recovery, 40.4% lower, RR 0.60, p = 0.24, treatment 7 of 89 (7.9%), control 12 of 91 (13.2%), NNT 19, cough.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Rohani et al., 18 Aug 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Iran, peer-reviewed, mean age 39.4, 6 authors, study period 1 May, 2020 - 1 September, 2020, trial IRCT46974.
Contact: karimymahmood@yahoo.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin AAll
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit